Your browser doesn't support javascript.
loading
[Clinical study of Bushen Culuan Formula in treatment of ovulatory disorder infertility caused by hyperprolactinemia].
Ma, Kun; Li, Jia-Ni; Liu, Xiao-Qian.
Afiliação
  • Ma K; Xiyuan Hospital, China Academy of Chinese Medical Sciences Beijing 100091, China.
  • Li JN; Xiyuan Hospital, China Academy of Chinese Medical Sciences Beijing 100091, China.
  • Liu XQ; China Association of Chinese Medicine Beijing 100029, China.
Zhongguo Zhong Yao Za Zhi ; 49(8): 2016-2022, 2024 Apr.
Article em Zh | MEDLINE | ID: mdl-38812218
ABSTRACT
This paper aims to study the therapeutic effect and safety of Bushen Culuan Formula in the treatment of patients with infertility caused by hyperprolactinemia. Sixty patients with infertility caused by hyperprolactinemia of kidney deficiency and blood stasis were divided into the treatment group(Bushen Culuan Formula + Bromocriptine Mesylate Tablets placebo) and the control group(Bromocriptine Mesylate Tablets + Bushen Culuan Formula placebo), and ovulation rate, pregnancy rate, serum sex hormones, basal body temperature(BBT), and traditional Chinese medicine(TCM) symptom scores were observed. The results showed the clinical effective rate was 90.00% in the treatment group and 80.00% in the control group. The treatment group was able to significantly reduce the PRL level and increase the pregnancy rate, and it was superior to the control group in increasing the BBT biphasic ratio, improving the TCM symptom scores, and enhancing the ovulation rate. The results show that Bushen Culuan Formula is safe and reliable in treating ovulatory disorder infertility caused by hyperprolactinemia, with remarkable effects.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Limite: Adult / Female / Humans / Pregnancy Idioma: Zh Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Limite: Adult / Female / Humans / Pregnancy Idioma: Zh Ano de publicação: 2024 Tipo de documento: Article